2024-516790-78-00尚未招募2 期
Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324)
Universitat Heidelberg12 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2025年3月24日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
- 试验地点
- 12
- 主要终点
- Progression-free survival rate at 12 months (PFS@12) according to RECIST 1.1, defined as the proportion of patients alive with non-progressive disease 12 months after enrollment and estimated by the Kaplan-Meier method.
研究概览
简要总结
To evaluate the efficacy of osimertinib along with chemotherapy in stage IV NSCLC patients with atypical EGFR mutations (EGFR mutations in Exons 18-21 excluding L858R, Exon 19 del, Exon 20 Ins or T790M mutation).
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Patient has provided written informed consent
- •Patient has adequate hepatic, renal and bone marrow function: a) Hemoglobin ≥ 9.0 g/dL b) Absolute neutrophil count ≥ 1.5 x 109 /L c) Platelets ≥ 100 x 109 /L d) Calculated creatinine clearance ≥ 60 mL/min (use of CKD-EPI formulation is highly recommended) and creatinine ≤ 1.5x upper limit of normal (ULN) e) Serum bilirubin ≤ 1.5 x ULN (or ≤ 3 x ULN in the presence of documented Gilbert‘s Syndrome [unconjugated hyperbilirubinemia] or liver metastases) f) AST/ ALT and alkaline phosphatase ≤ 2.5 x ULN (or ≤5 times ULN in the presence of liver metastases) g) International normalized ratio (INR)/ Activated partial thromboplastin time (aPTT) ≤1.5 × ULN unless participant is receiving anticoagulant therapy as long as PTT is within therapeutic range of intended use of anticoagulants
- •Female patients who are considered as woman of childbearing potential (WOCBP) must agree to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods that result in a failure rate of <1% per year during the treatment period as well as up to 2 months after last dose of osimertinib or 6 months after last dose chemotherapy, whatever is later (see section 5.2.6).
- •WOCBP must have a negative serum pregnancy test and not be breast-feeding prior to start of the trial treatment
- •Male patients with WOCBP partners must agree to remain abstinent (refrain from heterosexual intercourse) or use barrier contraceptive during the treatment period as well as up to 4 months after last dose of osimertinib, 3 months after last dose of pemetrexed or up to 6 months after last dose of carboplatin or cisplatin, whatever is later. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy (see section 5.2.6).
- •Patient is 18 years or older at time of signing the informed consent form
- •Patient has histologically or cytologically confirmed stage IV NSCLC (adenocarcinoma)
- •Patient did not receive prior systemic treatment for metastatic stage
- •Patient has one or more EGFR mutations in Exons 18-21 excluding L858R, Exon 19 del, Exon 20 Ins or T790M mutation (tested locally)
- •Patient has negative molecular testing for ALK and ROS1 alterations (tested locally)
- •Patient has ECOG performance status ≤ 1
- •Patient must have a life expectancy ≥ 12 weeks
- •Patient has at least one measurable lesion according to RECIST v1.1
排除标准
- •Mixed histology (small-cell and non-small cell or non-squamous and squamous; patients exhibiting the latter expression pattern may be eligible if the adenocarcinoma part predominates in >50% of analyzed tumor tissue)
- •Patient has refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow tablets or previous significant bowl resection that would preclude adequate absorption of osimertinib
- •Patient has any of the following cardiac criteria: • Mean resting corrected QT interval (QTc) > 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value • Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second degree heart block • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: Serum/plasma potassium < LLN; Serum/plasma magnesium < LLN; Serum/plasma calcium < LLN) , congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes
- •Leptomeningeal disease
- •Patient has past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
- •Known additional malignancies other than NSCLC, either untreated or having required active treatment within the past 3 years
- •Known allergy or hypersensitivity to any component of the chemotherapy regimen or to osimertinib or any constituents of the products
- •Any co-existing medical condition that in the investigator’s judgement will substantially increase the risk associated with the patient’s participation in the trial.
- •Patients having received any prior therapy with an EGFR TKI
- •Patient is candidate for complete removal of oligometastatic disease. If patients refuse to undergo surgery/ablations they are allowed into the trial
- •Patient received treatment with an investigational drug within five half-lives of the compound or 3 months before start of the trial treatment, whichever is greater
- •Patient is currently receiving (or unable to stop prior start of the trial treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 weeks prior) (see Appendix 3). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4
- •Patient has symptomatic, neurologically unstable CNS metastases or requiring increasing doses of steroids to manage CNS symptoms within 2 weeks prior to trial entry (maximal acceptable dose must be ≤ 10 mg of prednisolone)
- •Patient has any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of start of trial treatment, with exception of alopecia and grade 2 prior platinum-therapy-related neuropathy
- •Patient has any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator’s opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol
- •Patient has known active infection (e.g. patients receiving treatment for infection) including hepatitis C and human immunodeficiency virus (HCV/ HIV), or active uncontrolled HBV infection. Screening for chronic conditions is not required. Patients with chronic/ resolved HBV are eligible if they meet the following criteria: • Negative for hepatitis B surface antibody (HBsAb) and positive for hepatitis B core antibody (HBcAb). In addition, patients must be receiving anti-viral prophylaxis for 2- 4 weeks prior to study treatment OR • Positive for HBsAg, but for > 6 months have had transaminases levels below ULN and HBV DNA levels below <100 IU/mL (i.e., are in an inactive carrier state). In addition, patients must be receiving anti-viral prophylaxis for 2-4 weeks prior to study treatment
结局指标
主要结局
Progression-free survival rate at 12 months (PFS@12) according to RECIST 1.1, defined as the proportion of patients alive with non-progressive disease 12 months after enrollment and estimated by the Kaplan-Meier method.
Progression-free survival rate at 12 months (PFS@12) according to RECIST 1.1, defined as the proportion of patients alive with non-progressive disease 12 months after enrollment and estimated by the Kaplan-Meier method.
次要结局
- Progression-free survival rate (PFS), defined as time from enrollment to the date of progression according to RECIST 1.1 or death due to any cause
- Overall survival (OS), defined as time from enrollment to the date of death due to any cause
- Objective response rate (ORR), defined as rate of patients achieving complete response (CR) or partial response (PR) according to RECIST 1.1 as best overall response
- Toxicity according to CTCAE 5.0
- Progression-free survival rate (PFS2) as defined by time from initial trial randomization to second disease progression or death from any cause
研究者
Dr. Maike Collienne
Scientific
Universitat Heidelberg
研究点 (12)
Loading locations...
相似试验
招募中
2 期
OSIBOOST 2: Improving Osimertinib cost-effectiveness in Non-Small Cell Lung Cancer treatment using dose-modification and pharmacokinetic boosting with cobicistat2023-505700-35-00University Hospital Maastricht60
招募中
2 期
A trial to learn how well osimertinib with savolitinib works in people with non-small cell lung cancer (NSCLC) that has gotten worse after initial treatment with osimertinib.2024-512564-58-00AstraZeneca AB135
招募中
2 期
First line treatment with osimertinib in non-small cell lung cancer, coupled with studies on biological samples.2024-513881-20-00Vestre Viken HF96
招募中
3 期
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)2024-516598-60-00Mirati Therapeutics Inc.196
招募中
3 期
A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer2023-506576-27-00Janssen - Cilag International170